Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (111-120 of 459) with videos related to

Pageof 46
Sort By:
European Urology|June 13, 2018
Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial TumorsMatteo Santoni, Francesco Piva, Alessandro Conti, et al.
Targeted Oncology|February 6, 2016
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Alessandra Modena, Francesco Massari, Chiara Ciccarese, et al.
Pathology|November 14, 2014
Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell traitMarina Scarpelli, Roberta Mazzucchelli, Antonio Lopez-Beltran, et al.
Cancer Treatment Reviews|August 19, 2017
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapiesMatteo Santoni, Federico Guerra, Alessandro Conti, et al.
Pharmacology & Therapeutics|July 21, 2023
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?Martina Catalano, Giuseppe Procopio, Pierangela Sepe, et al.
Future Oncology (London, England)|January 20, 2022
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Recent Patents on Anti-Infective Drug Discovery|May 29, 2012
Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicityMatteo Santoni, Mimma Rizzo, Luciano Burattini, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 1, 2021
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysisMatteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Diagnostics (Basel, Switzerland)|December 19, 2020
Exploring the Spectrum of Kidney CiliopathiesMatteo Santoni, Francesco Piva, Alessia Cimadamore, et al.
Oncotarget|October 17, 2015
Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cellsMaria Beatrice Morelli, Consuelo Amantini, Matteo Santoni, et al.
Pageof 46

Showing results (111-120 of 459) with videos related to

Sort By:
Pageof 46
European Urology|June 13, 2018
Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial TumorsMatteo Santoni, Francesco Piva, Alessandro Conti, et al.
Targeted Oncology|February 6, 2016
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Alessandra Modena, Francesco Massari, Chiara Ciccarese, et al.
Pathology|November 14, 2014
Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell traitMarina Scarpelli, Roberta Mazzucchelli, Antonio Lopez-Beltran, et al.
Cancer Treatment Reviews|August 19, 2017
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapiesMatteo Santoni, Federico Guerra, Alessandro Conti, et al.
Pharmacology & Therapeutics|July 21, 2023
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?Martina Catalano, Giuseppe Procopio, Pierangela Sepe, et al.
Future Oncology (London, England)|January 20, 2022
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Recent Patents on Anti-Infective Drug Discovery|May 29, 2012
Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicityMatteo Santoni, Mimma Rizzo, Luciano Burattini, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 1, 2021
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysisMatteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Diagnostics (Basel, Switzerland)|December 19, 2020
Exploring the Spectrum of Kidney CiliopathiesMatteo Santoni, Francesco Piva, Alessia Cimadamore, et al.
Oncotarget|October 17, 2015
Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cellsMaria Beatrice Morelli, Consuelo Amantini, Matteo Santoni, et al.
Pageof 46